A perspective on HPK1 as a novel immuno-oncology drug target
Open Access
- 8 September 2020
- journal article
- review article
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 9
Abstract
In this perspective review, the role Hematopoietic Progenitor Kinase 1 (HPK1) in tumor immunity will be reviewed, with special emphasis on how T cells are negatively-regulated at different junctures of cancer-immunity cycle by this regulatory kinase. The review will highlight the strengths and weaknesses of HPK1 as a candidate target for novel immuno-oncology (IO) drug development that is centered on the use of small molecule kinase inhibitor to modulate the immune response against cancer. Such a therapeutic approach, if proven successful, could supplement the cancer cell-centric standard of care therapies in order to fully meet the therapeutic needs of cancer patients.Keywords
Funding Information
- Tisch Cancer Institute (Pilot Project 19-2659)
- Pfizer (CTI Program of Pfizer Pharmaceuticals 08-0083)
This publication has 95 references indexed in Scilit:
- A Death Effector Domain Chain DISC Model Reveals a Crucial Role for Caspase-8 Chain Assembly in Mediating Apoptotic Cell DeathMolecular Cell, 2012
- Down-regulation of B Cell Receptor Signaling by Hematopoietic Progenitor Kinase 1 (HPK1)-mediated Phosphorylation and Ubiquitination of Activated B Cell Linker Protein (BLNK)Journal of Biological Chemistry, 2012
- Release of serine/threonine-phosphorylated adaptors from signaling microclusters down-regulates T cell activationJournal of Cell Biology, 2011
- Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivityNature Biotechnology, 2011
- The Adapter Protein SLP-76 Mediates “Outside-In” Integrin Signaling and Function in T CellsMolecular and Cellular Biology, 2009
- Hematopoietic progenitor kinase 1 is a critical component of prostaglandin E2-mediated suppression of the anti-tumor immune responseCancer Immunology, Immunotherapy, 2009
- Phosphorylation of CARMA1 by HPK1 is critical for NF-κB activation in T cellsProceedings of the National Academy of Sciences, 2009
- T Cell ActivationAnnual Review of Immunology, 2009
- Pro-inflammatory prostaglandins and progression of colorectal cancerCancer Letters, 2008
- A novel pathway down-modulating T cell activation involves HPK-1–dependent recruitment of 14-3-3 proteins on SLP-76Journal of Experimental Medicine, 2007